CRVO

CervoMed Inc. (NASDAQ:CRVO) is a clinical-stage biotechnology company founded in 2008 and headquartered in Boston, Massachusetts. The company focuses on developing innovative treatments for neurodegenerative diseases, particularly targeting conditions that affect cognitive function and brain health. CervoMed's primary asset is <b>neflamapimod</b>, an orally administered small molecule drug candidate designed to penetrate the brain barrier and treat various forms of dementia and neurological conditions. As a clinical-stage company, CervoMed does not yet generate revenue from product sales but instead relies on funding from investors and potential partnerships to advance its drug development programs through clinical trials toward regulatory approval.